News

Forum Spotlights Venous Drainage/MS Link


 

She cited previous research programs in gender differences in MS, genetics, and myelin repair mechanisms, as examples of the society's role in encouraging research in “underexplored” areas.

On Dec. 16, 2009, the society invited researchers worldwide to submit applications for funding and proposals for further research on CCSVI in MS. The deadline for submissions was Feb. 9, and decisions are expected mid-June.

In an interview, Dr. O'Looney declined to specify how much money has been allocated by the society. She said that she expects more than one project to be funded and that the hope is that definitive information about the CCSVI-MS association would be available within 2 years.

“We felt that answering this question was critical before patients underwent interventional treatment, which carries its own risks,” Dr. O'Looney said.

Dr. Zivadinov (left), Dr. Miller (third from left), and Dr. Zamboni (standing) discuss CCSVI in a forum held at the AAN meeting.

Source Courtesy National MS Society

Pages

Recommended Reading

NAA Discerns MS From Neuromyelitis Optica
MDedge Neurology
Lesions May Resurge After Halting Natalizumab
MDedge Neurology
Natalizumab Succeeds in Post-Marketing Trial
MDedge Neurology
Potential Methods for PML Surveillance Programs Outlined
MDedge Neurology
IL-2 Receptor Inhibitor Reduced Lesions in MS
MDedge Neurology
Neutralizing Antibodies to Interferon Beta May Worsen MS
MDedge Neurology
News Roundup: New and Noteworthy Information
MDedge Neurology
Natalizumab and MS—Where Do We Stand?
MDedge Neurology
Commentary: Natalizumab and MS—Where Do We Stand?
MDedge Neurology
Zeroing in on Tuberous Sclerosis Complex
MDedge Neurology